Breaking: Britain and the United States just locked in a zero-tariff agreement on pharmaceutical products. This deal marks a significant shift in transatlantic trade relations, potentially reshaping supply chains and pricing structures across the healthcare sector. The agreement eliminates tariff barriers that previously impacted drug imports and exports between the two nations. Market watchers are now analyzing how this policy change might ripple through broader economic indicators and investor sentiment.